



Dr. Reddy's

**FOR HEALTH.
FOR LIFE.**

Cardiovascular, Respiratory, Gastrointestinal and Oncology

Dr. Reddy's Limited

Dr. Reddy's
Limited



HIGHLIGHTS

REVENUES	₹ 189.7 billion
EBITDA	₹ 47.4 billion
PROFIT AFTER TAX	₹ 17.2 billion
DILUTED EPS	₹ 103.65

As on March 31, 2021, we have received approval (92%) of the IV filings and we have 'First-in-class' status.

DMF FILINGS
14 DMFs filed in the US.

Dr.Reddy's

FOR HEALTH. FOR LIFE.

Connecting science, technology and innovation

Annual Report 2020-21

Good Health
Can't Wait.

